Clinical Trials Logo

Filter by:
NCT ID: NCT04394546 Active, not recruiting - Stroke Clinical Trials

CHAMPION-AF Clinical Trial

CHAMPION-AF
Start date: October 15, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.

NCT ID: NCT04394481 Completed - Analgesia Clinical Trials

Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery

INDEX
Start date: September 28, 2020
Phase: Phase 4
Study type: Interventional

The main objective of the study is to demonstrate the efficacy of Dexmedetomidine on the prolongation of analgesia obtained by interscalenic bloc of the brachial plexus and intravenous injection of Dexamethasone (efficacy objective).

NCT ID: NCT04394429 Recruiting - Sars-CoV2 Clinical Trials

Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation

TubeObs-Covid
Start date: April 24, 2020
Phase:
Study type: Observational

The COVID-19 pandemic is very present in our region, the Grand-Est region is considered as one of the first COVID-19 epicentres in France. COVID-19 causes an acute respiratory distress syndrome requiring prolonged mechanical ventilation in resuscitation.

NCT ID: NCT04394195 Completed - Clinical trials for CORONAVIRUS INFECTIONS

sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?

COVIDsFlt1
Start date: April 3, 2020
Phase:
Study type: Observational

Short description of the protocol intended for the lay public. Include a brief statement of the study hypothesis (Limit : 5000 characters) The management of critically-ill patients with organ failure due to COVID-19 represents a major healthcare burden. While endothelial inflammation has been reported in these patients, the pathophysiological mechanisms remain incompletely elucidated.

NCT ID: NCT04394052 Recruiting - Bone Neoplasm Clinical Trials

Novel Imaging Techniques for the Characterization of Musculoskeletal Tumors II

TUMOSTEO II
Start date: June 1, 2020
Phase:
Study type: Observational

This study aims at evaluating the value of various artificial intelligence based techniques to improve the characterization and image post-processing for patients with musculoskeletal tumors.

NCT ID: NCT04393753 Completed - Clinical trials for Merkel Cell Carcinoma

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

MERKLIN2
Start date: October 13, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma that have progressed on a previous therapy with an anti-PD-(L)1 antibody

NCT ID: NCT04393701 Recruiting - Clinical trials for Lysosomal Storage Diseases

A Pilot Study for Systematic Neonatal Screening for Lysosomal Storage Diseases Using Tandem Mass Spectrometry

LysoNeo
Start date: March 8, 2021
Phase: N/A
Study type: Interventional

The study will include all newborns in Normandie region for 3 years (about 105,000 births) for whom signed consent by one (or two) parents will be collected. Based on our previous pilot study (2011) assessing MCAD and PKU using tandem mass spectrometry-based method in Normandie region in which informed consents have been signed for all newborns (43,000) but we are expecting a great willingness to participate to this project. Thus, we are aiming to include 100,000 newborns, and the study will be continued until we reach at least this target. The primary objective is to evaluate the epidemiology of MPS1 and Pompe disease using dried blood samples in the first cohort of neonates tested in France (Normandie region).

NCT ID: NCT04393428 Completed - COVID-19 Clinical Trials

Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)

COVID-AKI
Start date: March 1, 2020
Phase:
Study type: Observational

Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.

NCT ID: NCT04393402 Recruiting - COVID Clinical Trials

Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19)

LUS-COVID19
Start date: March 20, 2020
Phase:
Study type: Observational

It might be necessary with Sars-Cov2 pneumopathy patient to repeat thoracic images, the tomodensitometry ones in particular. This task is difficult and nearly impossible for several reasons: respiratory and hemodynamic unstable patient, prone position and due to the high contagious nature of the disease. The lung ultrasound is an easy tool, fast (between 5 and 10 minutes) and as a limited training. In the context of the Sars-Cov2 epidemic, Buonsenso and al case report depict the first lung ultrasound for a Covid 19 patient. Peng and al in Intensive Care Medicine accentuate the usefulness of this particular technic. In the American Journal of Respiratory and Critical Care Medicine, a study has been published as a point-of-care, in which the doctors reported using the lung ultrasound with intensive and critical care patient. In Critical Care 2016, it has been showed that ultrasound allowed with neat precisions, to predict severe ARDS patient response to the prone position, all-cause. Another researchers team found a good correlation between lung ultrasound, the SOFA, APACHE II, CPIS score, and patient mortality. And a new applicability in the pulmonary recruitment by PEEP titration has been presented. The aim of this study is to evaluate the lung ultrasound in Covid19 ARDS.

NCT ID: NCT04393233 Recruiting - Clinical trials for Rheumatoid Arthritis

Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

RHUMACOVID
Start date: April 23, 2020
Phase:
Study type: Observational

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.